Company
Every investor coverage indicates participated in a round GlaxoSmithKline raised.
Companies GlaxoSmithKline acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Brett Haumann | Vice President of Clinical Development (former) | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming GlaxoSmithKline. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Blackbird's interview with MoreGoodDays co-founder Helena Ngo covers her corporate brand career, meeting co-founder Neala Fulia in Startmate's 2021 Founder Fellowship, and how the chronic-pain healthtech startup wins customers.
Roundup covering Victorian zero-emission bus trials, Frew Foods' planned plant expansion, 5B's layoffs and completed capital raise, Wellnex Life's convertible note raising, SafetyCulture investing in Inauro, plus wind farm and university research news.
Clinical-stage biotech Aravax has added pharma veteran Dr Brett Haumann, formerly of ReViral, Theravance, GSK and Aimmune, as a non-executive director ahead of a Phase 2 study of its peanut allergy therapy PVX108.
ChemGenex Pharmaceuticals has hired Thomas DeZao as senior vice president and chief commercial officer to lead US commercialisation of its leukemia drug omacetaxine; his past roles span Genitope, Corixa/Coulter, Asta Medica and Chiron.
Peptech announces GSK has completed its buyout of Domantis, the UK biotech in which the Australian company held a stake, yielding it 71.3 million pounds and a large gain on its original investment.